Tumor-associated antigen recognized by gamma-delta T-cell receptor

The phrase "Tumor-associated antigen recognized by gamma-delta T-cell receptor" refers to a heterogeneous group of antigens that are detected by the γδ T cell receptor (γδ TCR), which is a unique type of TCR found on γδ T cells, a minority subset of T lymphocytes. Unlike conventional αβ T cells, γδ T cells can recognize a variety of antigens without the need for MHC-mediated antigen presentation. The specific molecular identities of all γδ TCR ligands remain incompletely characterized, but include stress-induced self-molecules (such as annexin A2, EPCR, and Ephrin type-A receptor 2) frequently upregulated in cancerous or infected cells[3]. Recognition of these antigens can result in γδ T cell activation, leading to direct cytotoxicity against transformed cells and modulation of the broader immune response. The diversity of γδ TCR ligand specificity and function means that this is not a single molecular entity but a functional class of antigens[1][3][4]. As such, the target is not precisely a molecule but a group of related targets, making the term "Tumor-associated antigen recognized by gamma-delta T-cell receptor" non-canonical and imprecise as a drug target entity. Key limitations: - This is not a single molecule, but a functional/phenotypic class encompassing many potential ligands. - The target lacks a canonical abbreviation or universally recognized “full name.” - The known antigens recognized by the γδ TCR continue to expand, and the major ligands are still a topic of ongoing research[3]. - Drugs/therapies are being developed to harness or enhance γδ T cell recognition, but do not directly target this class of antigens as a unit.

Other names

Tumor-associated antigens (as recognized by gamma-delta TCR)γδ TCR ligandsγδ T cell tumor antigens

Recognition by γδ TCR leads to activation of γδ T cells, which can kill tumor cells directly or stimulate the broader immune response via cytokines[1][4]. Some molecules (e.g., bisphosphonates) can increase the accumulation of certain antigens recognized by γδ T cells, thereby boosting their anti-tumor function, but no direct small molecule or antibody drugs target this entire antigen class[3].